NOVELTY - Ethyl 3-(1-(2-(((4-cyanophenyl)amino)methyl)-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido)propanoate methanesulfonic acid (I), is new.    USE - Compound (I) is used for preparing ethyl 3-1-2-4-carbamimidoylphenyl-amino-methyl-1-methyl-1H-1,3-benzodiazol-5-yl-N-pyridin-2-yl-formamido propanoate methanesulfonic acid used for preparing l-methyl-2-N-4-N-n-hexyloxycarbonyl amidino phenyl-aminomethyl benzimidazol-5-yl-carboxylicacid-N-2-pyridyl-N-2-ethoxy carbonylethyl amide compound e.g. dabigatran etexilate and for preparing dabigatran etexilate salts including including mesylate, oxalate, fumarate and camphor sulfonate, and its crystalline form chosen from crystalline form-S and crystalline form-M (all claimed) and in pharmaceutical composition.    ADVANTAGE - Compound (I) is prepared by safe, economical, environmentally-friendly and simple process.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:    (1) ethyl 3-(1-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido)propanoate methanesulfonic acid;    (2) crystalline form-M of compound (I), which has peaks at 2 theta of 4.9 plus minus 0.2 degrees , 14 plus minus 0.2 degrees , 14.6 plus minus 0.2 degrees , 16.3 plus minus 0.2 degrees , 18.4 plus minus 0.2 degrees and 22.4 plus minus 0.2 degrees based on powder X-ray diffraction pattern, absorption peaks at 3345, 2216, 1174 and 1032 cm-1 based on infrared spectroscopy, and differential scanning calorimetry thermogram showing an endotherm at 195.24 degrees C;    (3) crystalline form-N of ethyl 3-(1-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido)propanoate methanesulfonic acid, which has peaks at 2 theta of 3.6 plus minus 0.2 degrees , 10.8 plus minus 0.2 degrees , 22.9 plus minus 0.2 degrees and 32.6 plus minus 0.2 degrees based on powder X-ray diffraction pattern, absorption peaks at 3155, 1179 and 1044 cm-1 based on infrared spectroscopy, and differential scanning calorimetry thermogram showing endotherm at 199.65 degrees C;    (4) preparation of ethyl 3-(1-(3-amino-4-(methylamino)phenyl)-N-(pyridin-2-yl)formamido)propanoate, which involves reducing ethyl 3-(1-(4-(methylamino)-3-nitrophenyl)-N-(pyridin-2-yl)formamido)propanoate with reducing agent chosen from iron-acetic acid and iron-hydrochloric acid in solvent;    (5) preparation of ethyl 3-(1-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido)propanoate methanesulfonic acid, which involves reacting compound (I) with ammonia source and/or ammonia gas in presence of hydrogen chloride gas and Lewis acid in solvent;    (6) preparation of 1-methyl-2-(N-(4-(N-n-hexyloxycarbonyl amidino) phenyl)aminomethyl)benzimidazol-5-yl-carboxylicacid-N-(2-pyridyl)-N-(2-ethoxy carbonylethyl) amide (dabigatran etexilate), which involves reacting n-hexanol and N,N-carbonyldiimidazole in solvent, reacting with ethyl 3-(1-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido)propanoate methanesulfonic acid in presence of base in solvent;    (7) purifying ethyl 3-(1-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido)propanoate methanesulfonic acid which involves dissolving ethyl 3-(1-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido)propanoate methanesulfonic acid in alcoholic solvent, adding non-polar solvent chosen from ether, ester, ketone, nitrile, hydrocarbon and chloro solvent, stirring, filtering, drying, and obtaining crystalline form-N of ethyl 3-(1-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido)propanoate methanesulfonic acid;    (8) dabigatran etexilate (-)-camphor sulfonate salt;    (9) crystalline form-M of dabigatran etexilate (-)-camphor sulfonate, which has powder X-ray diffraction pattern having peaks at 2 theta of 4.9 plus minus 0.2 degrees , 5.3 plus minus 0.2 degrees , 18.6 plus minus 0.2 degrees , 6.2 plus minus 0.2 degrees , 11.6 plus minus 0.2 degrees , 17.3 plus minus 0.2 degrees , 18.8 plus minus 0.2 degrees and 20.5 plus minus 0.2 degrees ;    (10) amorphous form of dabigatran etexilate (-)-camphor sulfonate;    (11) crystalline form-S of dabigatran etexilate oxalate, which has peaks at 2 theta of 3.9 plus minus 0.2 degrees , 7.5 plus minus 0.2 degrees , 7.8 plus minus 0.2 degrees , 11.9 plus minus 0.2 degrees , 18.2 plus minus 0.2 degrees , 20 plus minus 0.2 degrees and 27 plus minus 0.2 degrees based on powder X-ray diffraction pattern;    (12) crystalline form-N of dabigatran etexilate fumarate, which has peaks at 2 theta of 4.9 plus minus 0.2 degrees and 5.2 plus minus 0.2 degrees based on powder X-ray diffraction pattern;    (13) preparation of crystalline form-M of dabigatran etexilate (-)-camphor sulfonate, which involves reacting dabigatran etexilate with (-)-camphor sulfonic acid in solvent chosen from ketone, ether, ester, alcoholic, polar aprotic and polar solvents, distilling off the solvent, adding alcoholic solvent, adding an ether solvent, filtering precipitated solid, and drying;    (14) preparation of amorphous dabigatran etexilate (-)-camphor sulfonate, which involves reacting dabigatran etexilate with (-)-camphor sulfonic acid in solvent chosen from ketone, ether, ester, alcoholic, polar aprotic and polar solvent, distilling off the solvent, adding solvent chosen from ketone, ester, ether and hydrocarbon solvent, heating, stirring, filtering, and drying;    (15) preparation of crystalline form of dabigatran etexilate salt, which involves dissolving dabigatran etexilate in acetone, adding a solution of acid e.g. oxalic acid or fumaric acid dissolved in acetone, stirring, filtering the solid, and then drying;    (16) preparation of crystalline form-I of dabigatran etexilate mesylate, which involves dissolving dabigatran etexilate in acetonitrile, adding solution of methane sulfonic acid dissolved in acetonitrile, stirring, filtering, and drying;    (17) usage of compound (I) and ethyl 3-(1-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido)propanoate methanesulfonic acid for preparing high-purity dabigatran etexilate and its salts including mesylate, oxalate, fumarate and camphor sulfonate; and    (18) dabigatran etexilate mesylate, which has particle size distribution of d(0.1) of less than 50 mu m, d(0.5) of less than 100 mu m and d(0.9) of less than 200 mu m.